1

Bioactive Metabolites of Marine Algae, Fungi and Bacteria

Abstract

The chapter deals with the bioactive metabolites of marine algae, bacteria and fungi. The chemistry and biological activities of the bioactive brominated compounds, nitrogen heterocyclics, nitrogen-sulphur heterocyclics, sterols, terpenoids and sulfated polysaccharides isolated from marine algae, fungi and bacteria have been reviewed.

1.   Introduction

About 30,000 species of algae are found the world over which occur at all places where there is light and moisture and are found in abundance in sea. They supply oxygen to the biosphere, are a source of food for fishes, cattle and man. Algae are also used as medicine and fertilizers. A few algae that excrete toxic substances pollute marine water.

A majority of red algae and almost all the genera of brown algae except *Bodanella, Pleurocladia* and *Heribaudiella* occur in salt water. Many macroscopic green algae like *Codium, Caulerpa, Ulva* and *Enteromorpha* grow in shallow waters. The species of some genera, for example *Prasiola, Enteromorpha* and *Cladophora* grow both in fresh water and sea water. In sea water, many algae grow as phytoplankton (especially the dinoflagellates and certain blue-green algae). Other marine algae grow as benthos, epiphyte on other algae, parts of higher plants, rocks, stones, gravels, sand and mud. A small group of algae occurs in brackish water.

## 2.   Secondary Metabolites of Marine Algae

Extensive work has been done on the secondary metabolites of marine algae.[1] The work carried out on *Laurencia* species,[2] blue-green algae[3] and dinoflagellates[4] have been reviewed. Reports are available dealing with amino acids from marine algae,[5] guanidine derivatives,[6] phenolic substances,[7] bioluminescence,[8] carotenoids,[9] diterpenoids,[10] biosynthesis of metabolites,[11] indoles,[12] bioactive polymers[13] and halogenated compounds.[14,15]

3.   Bioactive Metabolites

Chemically the bioactive metabolites of marine flora include brominated phenols, oxygen heterocyclics, nitrogen heterocyclics, sulphur nitrogen heterocyclics, sterols, terpenoids, polysaccharides, peptides and proteins. The chemistry and biological activities of the compounds isolated have been reviewed.[16]

3.1 Brominated Phenols

The green, brown and red algae had been extensively analyzed for antibacterial and antifungal activities. The active principles isolated from *Symphyocladia gracilis, Rhodomela larix* and *Polysiphonia lanosa* were: 2,3-dibromobenzyl alcohol, 4,5-disulphate dipotassium salt (**1**), 2,3-dibromo-4,5-dihydroxybenzaldehyde (**2**), 2,3-dibromo-4,5-dihydroxybenzyl alcohol (**3**), 3,5-dibromo-p-hydroxybenzyl alcohol (**4**) and the 5-bromo-3,4-dihydroxybenzaldehyde (**5**). Virtually nothing is known about the physiological importance and the mechanism of biosynthesis of the bromo phenols. Their antialgal activity suggests that they may play a role in the regulation of epiphytes and endophytes. The bromo phenols may be biosynthesised through the shikimate pathway, and bromination may occur in the presence of suitable peroxide.[17]

1

2, R = CHO
3, R = CH$_2$OH

4

5

3.2 Brominated Oxygen Heterocyclics

The red algae *Laurencia* sp. have produced the diverse class of natural products.[18–22] *L. glandulifera*[19] and *L. nipponica*[23] had furnished two brominated oxygen heterocyclic compounds, laurencin (**6**)[22] and laureatin (**7**)[23], respectively. Laurencin ($C_{17}H_{23}BrO_3$), m.p. 73–74°C; $[\alpha]_D$ + 70.2° (CHCl$_3$) was isolated from the neutral fraction from methanol extract of the algae. The IR of the purified compound suggested the presence of a terminal methine (ν_{max} 3285 and 2180 cm^{-1}), an acetoxyl (1735 and 1235 cm^{-1}) and an ether (1168 and 1080 cm^{-1}) functions and *trans* and *cis* double bonds (3040, 950 and 750 cm^{-1}). The UV (in EtOH), λ_{max} 224 nm (ε 16,400) and 232 nm (ε 11,000) showed the presence of a conjugated diene or enyne. The NMR spectrum of the compound indicated the presence of four olefinic protons and an acetoxyl and ethyl groups. The presence of ethyl group was confirmed by isolation of CH$_3$—CH$_2$—CHO on ozonization of laurencin.

6   **7**

   Laurencin consumed four moles of hydrogen over platinum in ethyl acetate to yield octahydrolaurencin ($C_{17}H_{31}BrO_3$). On mild hydrolysis with KOH laurencin gave deacetyl laurencin ($C_{15}H_{21}BrO_2$) which was reconverted into original ester in good yield by treatment with acetic anhydride/pyridine. Reduction of octahydrolaurencin with LiAlH$_4$ afforded a debromoalcohol ($C_{15}H_{30}O_2$). Extensive NMR studies and spin decoupling experiments of the parent compound and the degradation products established structure (**6**) for laurencin.

   Laureatin ($C_{15}H_{20}Br_2O_2$) m.p. 82-83°C; $[\alpha]_D$+ 96° (CCl$_4$) has been isolated from the Japanese seaweed.[18] UV absorption λ_{max} 223 nm (ε12,800), 229 nm (ε10,400) and IR peaks at ν_{max} 3300, 2100, 1140, 1045, 975 and 965 cm^{-1} indicated that laureatin is an ether having a conjugated enyne group and contains neither hydroxyl nor carbonyl functions. NMR and spin decoupling experiments confirmed the presence of —CH$_2$—CH=CH—C≡CH

and —CH—CH$_2$—CH$_3$ groups. NMR spectrum of the compound also
       |
contained peaks for 6 protons at τ 5.0, 6.5; three one-proton septets at τ 5.12 and 5.87, a broad quartet at 5.62 and two multiplets centered at 6.2 and 6.35. These absorptions were ascribed to protons on carbons bearing an ether oxygen or a bromine atom. Laureatin consumed three moles of hydrogen over platinum catalyst in ethanol to yield hexahydrolaureatin. On treatment with zinc in refluxing acetic acid and then with dilute alkali hexahydrolaureatin

gave an unsaturated glycol. Laureatin was finally assigned structure (**7**) on the basis of chemical degradation studies and NMR spectroscopic data. Other brominated metabolites which have been isolated from *Laurencia nipponica*, are prelaureatin, laurallene, isolaurallene, bromofucin, and chlorofucin. The total syntheses of (+)-prelaureatin and (+)-laurallene have been achieved recently.[24] Laureatin (**7**) and isolaureatin exhibit significant larvicidal activity (IC_{50}) 0.06 and 0.50 ppm, respectively, in mosquitos. Brominated compounds isolated from marine algae, particularly bromophenols, are toxic and due to this they are not of clinical value.

3.3 Nitrogen Heterocyclics

Marine algae had yielded nitrogen containing heterocyclic compounds. Of these the most interesting compounds are domoic acid (**8**) and the kainic acid.


8

Domoic acid (**8**) ($C_{15}H_{21}NO_6$), m.p. 217°C (dec.): $[\alpha]_D$ – 109.6° [H_2O] an anthelmintic agent was first isolated from the alga *Chondria armata*.[25-29] The acid had UV λ_{max} 242 nm (log ε 4.42). Catalytic reduction of the compound with Pt-O_2 gave tetrahydrodomoic acid. Acetylation of the compound gave N-acetyl derivative, m.p. 121°C; $[\alpha]_D$–56° [H_2O]; λ_{max} 242 nm (log ε 4.48). Domoic acid showed marked anthelmintic activity. It was found to be very effective in expelling ascaris and pinworms without any observable side effects.

3.4 Kainic Acids

In Asia, the dried red alga *Digenea simplex* is widely used as an anthelmintic. It is found very effective in the treatment of ascariasis.[30] In the Mediterranean, extract of the alga *Corallina officinalis* is also used for the same purpose. Kainic acids as the active principles had been isolated from these algae. Of the kainic acids, α-kainic acid was the most active constituent. The structure (**9**) for α-kainic acid had been assigned by degradation studies[31] and confirmed by its synthesis.[32] The stereochemistry of α-kainic acid is shown in (**9**).[33]


9

Isomers of α-kainic acid had been isolated from alga *Digenea.* The isomers isolated are γ-allo-kainic acid (**10**)[34] and γ-kainic acid lactone (**11**).[35] L-α-kainic acid and L-α-allo-α-kainic acid are configurational isomers. In α-kainic acid the substituents at C-2 and C-3 and at C-3 and C-4 are *trans* and *cis*, respectively. In α-allokainic acid configurations at both the centres are *trans*. α-Kainic acid lactone was considered to be an artifact.[36] α-Kainic acid had been found effective in the treatment of ascariasis, with a single dose of 5 to 10 mg per adult resulting in a 40 to 70% reduction in the population of instestinal parasitic worms. α-Allokainic acid was found to have far less anthelmintic activity. Several preparations of kainic acids are available in the market, including 'Digenin' and 'Helminal' (The Merck Index, 1968). This represents one of the few instances in which clinically useful pharmaceutical product has been isolated from marine source.

10   **11**

3.5 Guanidine Derivatives

Certain shellfish periodically become poisonous to humans. It is now well established that the substance responsible is produced by a marine plankton, *Gonyaulax catenella.* At certain unpredictable time the red plankton multiply and cause "red tide". Although many fishes are killed by this "red tide", mussels and clams survive and concentrate the toxic principles, thus becoming poisonous to humans. The toxin isolated from the Alaskan butter clam, *Californian mussel*[37] and the alga *Gonyaulax catenella*[38-40] is called saxitoxin (**12**).

12

Saxitoxin ($C_{10}H_{19}N_7O_4$) when heated with P/HI in acetic acid, gave weakly basic compound I, $C_8H_{10}N_2O$ (m.p. 100-102°C), NMR analysis of I indicates

the presence of one C—CH$_3$ group.[41,42] On oxidation with potassium permanganate, urea and guanidinoacetic acid were obtained. Hydrogenation of I in the presence of platinum oxide (200 mole % hydrogen absorption) gave II, C$_8$H$_{14}$N$_2$O (m.p. 129-131°C) which also contained one C—CH$_3$ group. Strong acid hydrolysis of II led to the strongly basic, and highly hygroscopic oily diamine III, C$_7$H$_{16}$N$_2$ and on heating with Pd-C, III resulted in the formation of a substance which readily gave a positive Ehrlich test for pyrroles. On the basis of these data, it was concluded that III was a pyrrolidine and II was a saturated cyclic urea. This conclusion was fully supported with its ultraviolet absorption and its strong infrared absorption at 3410 and 1635 cm^{-1} in chloroform. The structure (**12**) to saxitoxin was assigned on the basis of degradation studies and spectroscopic analysis. Saxitoxin blocks nerve conduction by specifically interfering with the intital increase in sodium permeability of the membrane. The symptoms caused by the toxin include peripheral paralysis. In extreme cases, complete loss of strength in the muscles and finally death occurred which is caused due to respiratory failure.[43] Saxitoxin is absorbed from the gastro-intestinal tract. It produced no major vascular action. The oral LD$_{50}$ for toxin in various species of animals is reported. In man death had occurred following ingestion of as little as 1 mg of toxin.[44] The toxic compounds from marine algae appear to have biomedical potential. The compounds with neurotropic effects may yield important drugs.

3.6 Phenazine Derivatives

The marine alga *Caulerpa lamourouxii* is widely distributed in the Phillipines. The upper branches are eaten as a 'salad', despite their peppery and astringent taste. However, the alga is found toxic to some individuals. Chemical investigation of the alga had furnished caulerpicine, caulerpin, cholesterol, taraxerol, β-sitosterol and palmitic acid.[45] Caulerpin had also been isolated from *Caulerpa sertularioides, C. racemosa* var. *clavifera*[46] and caulerpicin from *C. racemosa*.[47]

Caulerpin (**13**) (C$_{24}$H$_{18}$N$_2$O$_4$) (M$^+$ 398) red prisms m.p. 317°C had λ$_{max}$ 222, 270, 292, 317 nm (ε 50,000, 27,000, 29,000 and 35,000); IR bands at 1684, 1631 and 1613 cm^{-1} suggesting the presence of carbonyl functions in conjugation with aromatic system. The NMR spectrum of the compound indicated the presence of 18 protons τ 6.17 (6H, 2 OMe), 2.4-3.0 (8H, m), 1.76 (2H, s) and 1.36 (2H, s). Aromatic protons signal at τ 2.4-3.0 and 1.79 and the IR bands at 730 and 920 cm^{-1} suggested the presence of two identically substituted aromatic ring systems. This was substantiated by elimination of 26 mass units (CH=CH) in the mass spectrum of caulerpin, caulerpinic acid and decarboxy caulerpin acid. Caulerpin contained two methoxy groups in the form of α,β-unsaturated methyl ether group [ν$_{max}$ 1685 cm^{-1}; NMR τ 6.17 (6H)]. Its mass spectrum supported the assignment m/z 398 (M$^+$), 366 (M$^+$–MeOH), 338 (366–CO), 306 (338–MeOH), 339 (M$^+$–CO$_2$Me) and 280 (M$^+$–2CO$_2$Me). The M$^+$ peak in the mass spectrum was the base peak.

Saponification of caulerpin with alcoholic KOH yielded caulerpinic acid ($C_{22}H_{14}N_2O_4$) (M^+ 370). The two exchangeable protons at τ 1.36 were due to secondary amino groups. The functions were conjugated with the two methoxy carbonyl groups as indicated by the low frequency carbonyl absorption (1685 cm^{-1}). The methoxy carbonyl groups were placed at the two α-positions of the two naphthalene rings conjugated with the NH groups at the β-positions. This arrangement accounted for the strong hydrogen bonding of the –NH protons. Caulerpinic acid when heated with copper bronze in quinoline at 200-210°C yielded a decarboxylated compound m.p. >300°C, (M^+ 282). On the basis of these studies caulerpin was assigned the structure α,β-dihydrodibeno[b,i]phenazine-5,12-dicarboxylate (**13**).[48] The stability of the compound was stated to favour the linear structure rather than the geometrical isomer. Caulerpin caused a mild anesthetic action when placed in the mouth, which resulted in numbness of the lips and tongue. In some people it produced toxic effects. The toxic syndrome had been reported to be some what similar to that produced by ciguatera fish poisoning.

13

3.7 Amino Acids and Amines

Extracts of the marine algae *Laminaria angustata* and *Chondria amata* are reported to contain agents with hypotensive and other pharmacological properties. Laminine (**14**), a choline like basic amino acid had been isolated from a number of marine algae.[49,50] The compound had been characterised as trimethyl(5-amino-5-carboxypentyl)ammonium oxalate (**14**). Several syntheses of laminine are reported.[51]


14

Laminine was isolated from water extracts of *Laminaria angustata* by amberlite ion exchange resin, IR-120 in acidic form and subsequent formation of reineckate and oxalate salts. The other amino acids isolated from this

source were: L-lysine, L-arginine, ethanolamine and choline. Laminine monocitrate was found to have a transitory hypotensive effect. Laminine, in general, depressed the contraction of excited smooth muscles. Laminine monocitrate had an LD_{50} in mouse, 394 mg/kg. It is considered to be a potentially useful pharmacological agent. Steiner and Hartmann[52] had reported the widespread occurrence of volatile amines, such as methylamine, dimethylamine, trimethylamine, ethylamine, propylamine, isobutylamine, isoamylamine, 2-phenylethylamine and 2-methylmercapto propylamine in red, green and brown algae. It is mentioned that biological activities of some of the extracts of the marine algae may be due to the presence of these amines.

3.8 Sterols

The presence of sterols in algae was first established by Heilbron et al[53] and later by Tsuda et al.[54] Gibbons et al[55] established the presence of 22-dehydrocholesterol and demosterol in red algae. However, later investigations showed that the sterol content of red algae were more varied than had been believed.[56] Idler et al[57] examined some species of red algae and found that the three species contained C_{27}, C_{28} and C_{29} sterols. An interesting feature of their result was the considerable variation in sterols content of four different samples of the alga *Rhodymenia palmata*. The percentage of demosterol, for example, varied from 97.2 to 7.7% in the mixture of sterols. Similary, cholesterol was detected in the concentration as high as 97.3% and as low as 2.1%. Cholesterol was again found the major sterol of Rhodophyta. Four species of algae, *Rhodymenia palmata, Porphyra purpurea, P. umbilicalis* and *Halosaccion ramentaceum* were found to contain desmosterol as the main sterol. However, *Hypnea japonica* was the only alga having 22-dehydrocholesterol as the major sterol. Of the 34 algae investigated by the Japanese and British investigators, only one sterol was detected in 25 species, while nine were found containing two sterols. Meunier et al[58] had given a comparative data of 14 species of Rhodophyta. All the species examined were found to contain cholesterol (**15**) as the major sterol except *Hypnea musciformis* in which 22-dehydrocholesterol (**16**) was detected in the highest concentration. *Hypnea japonica* was another example in which 22-dehydrocholesterol was present as the major sterol.

15   **16**

The distribution of sterols in algae had been reviewed.[58,59] Red algae contained primarily cholesterol (**15**). Several species contained large amount of demosterol (**17**), and one species contained primarily 22-dehydrocholesterol. Only a few rhodophyta contained traces of C_{28} and C_{29} sterols. Fucosterol (**18**) was the dominant sterol of brown algae. Most phaeophyta also contained traces of cholesterol and biosynthetic precursors of fucosterol.

17   **18**

The sterols of green algae were much more varied. The green algae contained chondrillasterol (**19**), poriferasterol (**20**), 28-isofucosterol, ergosterol and cholesterol.

19   **20**

24-Methyl cholesterol and sargasterol differ from fucosterol (**18**) in that the double bond is shifted to the C-28 position and is saturated at position 24. Sargasterol and fucosterol are isomers. The methyl group at position 20 in the former is α-oriented, whereas it is β-oriented in the latter. The sterols from marine algae are reported to be non-toxic and have the ability to reduce blood cholesterol level. They are also reported to reduce the tendency to form a fatty liver and excessive fat deposition in the heart.[60]

3.9 Sulfated Polysaccharides

The sulfated polysaccharides obtained from seaweeds are economically most important products due to their extensive use in food and medicine. Of the four major seaweed classes, the rhodophyceae (red algae), the phaeophyceae (brown algae), the cyanophyceae (blue-green algae) and the chlorophyceae (green algae), the first two classes produce polysaccharides of main interest. The red algae produce carrageenan, agar, agarose, furcellaran or Danish

agar. Alginic acid is obtained from brown algae. The use of seaweed extracts in food and medicine is reviewed.[61] Carrageenan are produced by species of *Chondrus, Eucheuma, Gigartina* and *Iridea.* There are different views on the structure of red seaweed polysaccharides.[62] It is generally suggested that carrageenans be defined as a polysaccharide comprising D-galactose units and derivatives linked alternatively α (1→ 3) and β (1→ 4). The ι, κ, λ and μ and other carrageenans represent variations of this primary and general form in which the galactose units are sulfated in a definite pattern and/or are present in the 3,6-anhydro form expressed generally as an A-B-A polymer. Pernas et al[63] however, do not agree on the validity of the above simplified structural approach to carrageenan. These workers believe that carrageenan is a continum of potassium precipitable material of continuously variable structural form. The ester sulphate groups are distributed randomly on all available hydroxyl groups in κ, in support of this hypothesis. The chemical structure of κ and λ carrageenans are still a matter of discussion. κ Carrageenan is precipitated from dilute solution with potassium ions, and is believed to consist primarily of alternating anhydrogalactose and sulphated galactose units linked α 1,3 and β 1,4. λ Carrageenan contains little anhydrogalactose. It consists chiefly of mono- and disulphate galactose units with, perhaps, the same alternating 1,3 and 1,4-linkages. Both κ and λ carrageenans are reported to be strong antigens.[64] The latter is more potent than the former. In general, they behave as typical carbohydrate antigens. λ Carrageenan is also reported to stimulate the growth of connective tissues.[64]

Chondrus crispus and *Gelidium cartilagineum*, the well-known sources of carrageenan and agar, respectively, had been found to possess antiviral properties attributed to the galactan units in the polysaccharides of both. The specific antiviral activity had been shown against influenza B and mumps virus in embryonated eggs even after 24 h inoculation. Carrageenan was also found as anticoagulant and antithrombic agent. The use of carrageenan in ulcer therapy had been studied intensively. It was thought at first that the polysaccharide inhibits the activity of pepsin and that its action in preventing ulcers was due to this property.[65] However, subsequent studies revealed that the polysaccharide plays a much more active role than enzyme inhibition. In fact, it was found that *in vivo*, pepsin was not inhibited by carrageenan. The polysaccharide reacts with the mucoid lining of the stomach and gives a protective layer through which pepsin and acid have difficulty in passing. The treatment of gastric and duodenal ulcers by carrageenan was enjoying considerable popularity in France and Great Britain. In many cases of ulcer carrageenan proved an effective cure.[66]

Alginic Acid
This polysaccharide is obtained from the brown seaweeds, especially from species of *Fucus* and *Macrocystis*. Chemically alginic acid (**21**) is made up of two monomers, the D-mannuronic acid and L-guluronic acid. Both these

D-Mannuronic acid   L-Guluronic acid

Alginic acid

21

sugar acids are stereoisomers and differ only in the configuration of the carboxyl group. The two uronic acid moieties in alginic acid are linked though β-1,4-glycosidic linkage in such a way that the carboxyl group of each unit is free, while the aldehydic group is sheilded by the glycosidic linkage. Biosynthesis of alginic acid is not yet known. An attractive hypothesis of its formation from guanosine diphosphate mannose has been proposed.[67]

Commercially, sodium alginate is extracted from giant brown seaweed (*Macrocystis pyrifera*), horsetail kelp (*Laminaria digitata*) and sugar kelp (*Laminaria saccharina*). Sodium alginate has been used mainly in the manufacture of ice cream where it serves as a stabilising colloid. It is also used in cosmetics and pharmaceuticals.[68] Calcium alginate is reputed to be a hemostatic agent which stimulates the clotting of blood *in situ* which is subsequently absorbed in the tissue.[69] Sodium alginate is reported to be a useful adjuvent in immunisation against two strains of influenza virus. Sodium alginate is also found effective in diminishing hyper calciuria in urolithiasis, and found useful in the treatment of esophagitis.

The most significant property of sodium alginate is the ability to remove strontium 85 and strontium 87 from the body without seriously affecting the availability of Ca, Na or K in the body.[70] This selective action of sodium alginate is of great potential to remove Sr-90 contamination due to fall out from atomic explosions.

Laminarin
It is essentially a linear polymer of β-1,3-glucan, with occasional branching points at C-6 and with a variable proportion of the glucose chains terminated at the potential reducing end with a molecule of mannitol, which can be sulphated to produce a compound with anticoagulant properties. Laminarin (**22**) occurs at certain times of the year to the extent of 35% of the dry weight of *Laminaria cloustoni*. It has been found that laminarin sulphate formed with two sulphate groups by glucose unit gives maximum stability and

Laminarin sulfate

22

anticoagulant activity. Two lower sulphated laminarins are also reported to have antilipidemic activity like that of heparin.[71,72]

Agar and Agarose

The red algae are the source of agar and agarose. Although these polysaccharides have no direct medicinal use, their use in biomedical research is well known. The genera *Gelidium, Gracilaria, Acanthopeltis* and *Pterocladia* of the Rhodophyceae are the main producers of these materials. Commercial agar generally contains 50-90% recoverable agarose. The structure of agarose was determined by Araki[73] and substantiated by others. Chemically, agarose is a linear polymer made up of repeating units of agarobiose (**23**) which, in turn, consists of a molecule of β-D-galactopyranose attached $1 \rightarrow 4$ to a molecule of 3,6-anhydro-L-galactose. These repeating units are linked $1 \rightarrow 3$ to form the agarose polymer. The presence of traces of sulphate and uronic acid residues have, thus far, been attributed to contamination by agaropectin. Many uses of agarose are described.[74] However, its use in immunology is most interesting.

Agarabiose unit

23

The interest to investigate the role of the polysaccharides in the body is growing. The sulphated seaweed polysaccharides are, in some ways, very much like the sulphated mucopolysaccharides of the body and yet, in some ways, are quite different. It is believed that, in some cases, the body may not distinguish the seaweed polysaccharides from those natural to it. In some other cases, they may be so much alike that reactions are started with them, but not finished in the normal manner, which may allow their use as inhibitors.

4. Marine Bacteria and Fungi

Bacteria and fungi are prime producers of the antagonistic substances in terrestrial environment. A similar role in the oceans from these organisms is expected. Indeed, this had been found true. Antibiotic, antiviral, antifungal, and antiyeast activities of these organisms had been reported.[75] Besides, a few growth stimulant properties which may be useful in studies on wound healing, carcinogenic properties, and in the study of cancers are reported.

Among the many bacteria showing antimicrobial activity, a variant of the ichthyotoxic *Pseudomonas piscicida*[75] exhibited marked antagonism to various micro-organisms. A red coloured bacterium obtained from Puerto Rico was found to excrete vitamin B and antibacterial substances into the sea water.[76] The bacteria and fungi from sea are also reported to produce substances which affect central nervous system (CNS), respiratory system (RS), neuromuscular system (NMS), autonomic nervous system (ANS), cardiovascular system (CVS) and gastrointestinal system (GI).[77] Some of the substances are known to produce local effects such as pain, necrosis, edema, parasthesias, pruritis etc. A marine isolate of the fungus *Cephalosporium acremonium* obtained from the sea near a sewage outfall of the coast of Sardina had been reported to produce a number of antibiotic substances.[78] A penicillinase sensitive antibiotic substance named antibiotic N active against Gram-negative bacteria, had been isolated from this source. This material was reported to be cephalosporin C (**24**)[79-81] which was different from cephalosporin N.

24

Other antibiotic substances isolated from *C. acremonium* were found to be penicillinase resistant and active against Gram-positive bacteria.[78] These substances were named cephalosporin P. This organism was also found to be a source of cephalothin (**25**), a semisynthetic derivative of cephalosporin C, having antibiotic action similar to that of benzylpenicillin but insensitive to penicillinase. It was active against a number of penicillin resistant *Staphylococcus* and some Gram-negative species of bacteria. A number of chemically-related antibiotic substances named cephalosporins P_1, P_2, P_3, P_4 and P_5 had been isolated from the marine species of fungus *Cephalosporium acremonium*.[82]

Cephalosporin P_1 ($C_{33}H_{52}O_8$) m.p. 147°C; $[\alpha]_D$ + 28° [$CHCl_3$] was a mono-basic triterpenic carboxylic acid. Methylation of the acid with CH_2N_2 at 0°C gave a monomethyl ester m.p. 196°C, while methylation at room temperature with CH_2N_2 produced a product containing nitrogen. The acid

25

and its methyl ester rapidly absorbed one mole of hydrogen in the presence of PtO$_2$ to give dihydrocephalosporin P and dihydrocephalosporin methyl ester, respectively. On standing in 1N NaOH at 37°C cephalosporin P lost an acetyl function to give a hydroxy acid m.p. 220°C. Besides, hydrolysis with alkali yielded a product which rapidly lactonised on acidification to give a neutral compound, m.p. 186°C. The chemical studies when combined with NMR and mass spectral data, structure (**26**) was assigned to cephalosporin P$_1$.[83] It exhibited good activity against *Bacillus mesentericus, Mycobacterium phlei* and *S. aureus in vitro*.[83]

26

Several bacteria, which produce antibiotic substances, had been isolated from the shallow water near Puerto Rico. A bromo pyrrole antibiotic has been isolated from *Pseudomonas bromoutilis*,[84] which showed activity against many Gram-positive bacteria (at levels of 0.06 mg/mL in broth assay test), but was not active by the subcutaneous route in mouse protection tests. The bromo compound (**27**) (C$_{10}$H$_4$Br$_5$NO) was unique in that over 70% of its weight consisted covalently bonded bromine. The mass spectrum of the compound suggested a molecular weight 553.5 and the presence of five bromine atoms from the clasture of isotope peaks. A preferential and sequential loss of one, two and three bromine atoms from the molecular ion together with loss of HCN was observed. Metastable ion peaks corresponding to a simple cleavage of the phenol and pyrrole portions were also discernible. The structure (**27**) for the antibiotic was finally established by X-ray crystallographic analysis[84] and confirmed by its synthesis.[85] Pyrrolnitrin (**28**), a chloropyrrole had been isolated from *Pseudomonas pyrrocinia*. Pyrrolnitrin (**28**) exhibited high antibiotic activity against dermatophytic fungi, particularly

27   28

against members of the genus *Trychophyton* and against many soil borne fungal plant pathogens like *Rhizoctonia solani* and *Fusarium sambucinum* and against foliar fungal pathogens like *Fusarium graminearum, F. culmorum* and *Pyrenophora tritici repentis*.[86] This compound was marketed in Japan under the name PYRO-ACE for the treatment of superficial dermatophytic infections.[86h] Its light sensitivity prevented the use of pyrrolnitrin (**28**) as a fungicide in plant protection. Recently, antimycobacterial activity was reported for (**28**) and related compounds.[86i] Biological activity of (**28**) at low concentrations was demonstrated to be due to the uncoupling of oxidative phosphorylation in *Neurospora crassa* and at higher concentrations due to inhibition of electron transport both in the flavin region and through cytochrome coxidase.[86l] However, recently it was reported that (**28**) leads to glycerol accumulation and stimulation of triacylglycerol synthesis resulting in leaky cell membranes and concomitant break down of biosynthetic activity followed by cessation of cell growth.[86m] It had been characterised as 3-chloro-4-(2-nitro-3-chlorophenyl)pyrrole. A synthesis of the antibiotic is reported.[87]

The formation of antibiotic substances of the types mentioned above gives the indication that the marine microbes are capable of producing new and unusual types of antibiotic substances than the terrestrial ones. Some of these bioactive substances would, undoubtedly, be found useful in medicine and pharmacology, while others could become of even greater interest than native product.

Serratia marcescens, a widely distributed non-pathogenic bacterium, had furnished a red coloured antibiotic named prodigiosin.[88-96] It exhibited high order of antibiotic and antifungal activities. The high toxicity of prodigiosin precluded its use as a therapeutic agent.

Studies on the marine phytoplanktons are few because of difficulty of growing the organisms and the low yield of secondary metabolites. However, several toxins related to saxitoxin are isolated from *Gonyaulax* species.[97-103] The cultured cells of the dinoflagellate *Ptychodiscus brevis*, yielded brevetoxin B, C and dihydrobrevetoxin B.[103-107] A unique feature of their structure is a chain of eleven, continuous *trans*-fused ether rings in the form of a flat ladder. *P. brevis* yielded two phosphorus containing toxins[108] GB-4 and

GB-1 which do not appear to be natural products since attempts to incorporate ^{32}P into GB-1 gave ambiquous results.[109,110] Two new polycyclic ethers, GB-5 and GB-6 closely related to okadaic acid, a toxin that was first found in sponges and later in dinoflagellate have been isolated from the cultured cells of *G. breve*.[111] The dinoflagellate *Dinophysis*, produces and transmits shellfish, toxins that are responsibe for diarrhoetic shellfish poisoning.[112] *Lyngbya majuscula* known to cause swimmer's itch has furnished several class of compounds.[113-126] Pukeleimides (A-F) showed activity against *Mycobacterium smegmatis* and *Streptococcus pyrogenes*.[113,127,128] Cyclic depsipeptide, majusculamide-C isolated from the organism inhibits the growth of fungal plant pathogen.[129] Aplysiatoxins and oscillatoxins isolated from blue-green algae *Schizothrix calcicola* and *Oscillatoria nigroviridis* possess antileukaemic activity but their high toxicity precludes their medicinal use. Cytotoxic and fungicidal nucleosides have been isolated from a variety of blue-green algae.[130] Anatoxin-a, an exogenic toxin of blue-green alga *Anabaena flosaquae*[131] is one of the most potent nicotinic receptor agonist. It is suggested that the analogues of anatoxin-a may be of clinical value for treating disorders associated with defects in cholinergic regions of the central nervous system.

Several species of green-algae of the genus *Halimeda* produce an ichthyotoxin which exhibits diverse biological activities.[132-134] It inhibits the growth of marine bacteria and fungi, cell division of fertilized sea-urchin eggs and the motility of sea-urchin sperms at 1 μg/mL. Avrainvilleol, a brominated metabolite of green algae, *Avrainvillea longicaulis* exhibits high order of antifeedant activity in reef fish and also inhibits the growth of microorganisms. The genera *Halimeda, Penicillus* and *Udotea* are found to contain highly active but unstable sesquiterpenoids and diterpenoids. Some of these diterpenoids exhibit cytotoxic and antimicrobial activities.[135,136] Prenylated aromatics with small side chains are relatively common in brown algae.[137] Several highly unsaturated C_{11} hydrocarbons are isolated from *Dictyopteris plagiogramma* and *D. australis*.[138,139] The function of these hydrocarbons have been studied in detail.[140,141] It has been observed that the sperm cells aggregate around the female gametes of brown algae which exude C_{11} hydrocarbons that attract the former and cause them to remain in the excited state in the vicinity of the latter. The sex attractants that have been identified are: ectocarpene from *Ectocarpus siliculosus*,[142] fucoserratene from *Fucus serratus*, multifidene from *Culteria multifida*, n-butyl-cyclohepta-2,5-diene from *Dictyota dichotoma*, desmarestene from *Desmarestia viridis* and tinavarrene from *Ascophyllum nodosum*. Tracing the origin of arsenic in lobsters and in fish, it has been found that the brown algae *Ecklonia radiata* concentrates arsenic in the form of arseno-sugars.[143,1444] Hydroxydictyodial from *Dictyota spinulosa* inhibits feeding in the omnivorous fish *Tilapia mossambica*.[145] Three ichthyotoxic and phytotoxic diterpenes are isolated from *Dilophus fasciola*.[146,147] Several diterpenes from *Dictyota* species exhibit significant cytotoxicity.[147] Two phlorotannins from *Ecklonia kurome* exhibit

antiplasmin inhibitory activity.[148-152] The pharmacological properties of laminine has been studied. It has been found that the compound at high doses does have a hypotensive action as a result of a ganglion blocking effect. Marine red algae have yielded a vast array of halogenated lipids, some of these exhibit CNS-depressant and hypotensive activities. Three brominated acetylenic compounds active against mosquito larvae have been obtained from *Laurentia nipponica*.[153] Trihydroxy benzyl methyl ethers having antibacterial activity against *Bacillus subtilis* are isolated from *Grateloupia filicina*.[154,155] Enantioselective synthesis of (–)-kainic acid possessing anthelmintic, insecticidal and neuroexcitatory activities, have been achieved. The symmetrical bisbenzyl ether from *Symphyocladia latiuscula* showed antifungal activity. 5-Iodo-5′-deoxytubercidin, an unusual nucleoside has been isolated from *Hypnea valentiae*.[156] The nucleoside caused pronounced relaxation of muscles, hypothermia in mice and blocked polysynaptic and monosynaptic reflexes.

5.   Micro Algae

Micro algae represent a subset of single cell microorganisms that generally grow autotropically using CO_2 as the sole carbon source and light as energy. These algae are ubiquitous in nature. Aquatic micro algae have been isolated in areas ranging from hot springs to glacial ice flows. There are over 50,000 different species of micro algae of which only a few have been characterised. Micro algae represent a major untapped resource of genetic potential for valuable bioactive agents and biochemicals. Phycocyanin and phycoerythrin are produced by cyanobateria (*Spirulina*), and recently have been used as fluorescent labelling agents. They are proteinaceous in structure and exhibit a high extinction coefficient. One future commercial application of micro algae could be in the production of special lipids. The omega-3-fatty acids found in the oils of certain cold-water marine fish are considered to be responsible to reduce incidence of coronary heart disease. These fatty acids are likely to originate from the phytoplankton in food chain. Many of these phytoplankton species are found to be rich in reserves of oils containing various amounts of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Exploiting autotrophy, micro algae are being used for the production of labelled biochemicals. This involves the substitution of tritiated water [^3H_2O] for ^1H_2O or $^{14}CO_2$ for $^{12}CO_2$ and results in the production of radioactively labelled biochemicals. Deuterium labelled compounds and also compounds labelled with ^{13}C are made using heavy water [D_2O] and $^{13}CO_2$, respectively. One can produce enrichment levels upto 100% depending on the isotope enrichment of the culture medium. These labelled biochemicals are of high value. Uses of the stable isotopically labelled compounds include production of very high stability deuterated lubricants. The most attractive source of the ^{13}C and ^2H-labelled compounds are autotrophic micro algae. If diagnostic tests are developed using these compounds, the market will increase

dramatically. Micro algae can also provide a "designer oil", specially tailored to the food industry. Further, commercial scale production of EPA from micro algae is an attractive proposition. Micro algae are also expected to furnish potent antiviral, antiAIDS, antibiotic and other bioactive agents.

The extract of cyanobacterium *Planktothrix* sp. exhibited embryotoxicity.[157] Changes in the culture conditions of *Lyngbya majuscula* had the greatest effect on production of its secondary metabolites.[158-165] Several leptosins were isolated from the marine alga *Leptosphaeria* sp. and their biological activity evaluated. Of these leptosin M exhibited significant cytotoxicity against human cancer cell lines.[166] Two new antiinflammatory macrolides, lobophorin A and B were isolated from a marine bacterium.[167] Water extract of marine diatom *Haslea ostrearia* exhibited anticoagulant activity.[168] Brominated anisoles and cresols were detected for the first time in the red marine alga *Polysiphonia sphaerocarpa*.[169] The sulfated polysaccharide of the red microalga *Porphyridium* sp. showed high order of antiviral activity against herpes simplex virus (HSV-1 and 2) both *in vitro* and *in vivo*.[170] Ten new sesquiterpenoids were isolated from the fungus *Drechslera dematioidea*. Of these drechserine E and G exhibited antiplasmodial activity against *Plasmodium falciparum* strains K1 and NF54.[171] Fucoidan, a sulfated polysaccharide from brown seaweed displayed anticoagulant and antithrombotic activities. It also had inhibitory action in the growth of Lewis lung carcinoma and B16 melanoma in mice.[172] Antitumor and immunomodulation activities were found in different molecular weight α-carrangeenans from *Chondrus ocellatus*.[173] 1-Hydroxy monocyclic carotenoid 3,4-dehydrogenase from a marine bacterium that produces myxol was identified.[174] This unique type of crt D is a valuable tool for obtaining 1′-HO-3′,4′-didehydromonocyclic carotenoids. Antarctic bacteria inhibited growth of food-borne microorganisms at low temperature.[175]

6.   Concluding Remarks

Marine algae have yielded a large variety of bioactive metabolites. Some of them have biomedical potential. Marine bacteria produce some of the most potent toxins such as saxitoxin and tetrodotoxin. The sulphated polysaccharides obtained from seaweeds are economically most important products. These are extensively used in food and medicine. The red algae are the source of agar and agarose. Although these polysaccharides have no direct medicinal use, however, their use in biomedical research is well known. Alginic acid obtained from brown seaweeds has several uses. The largest use of sodium alginate is in the manufacturing of ice cream. However, the most significant property of sodium alginate of biomedical value is that it has the ability to remove strontium 85 and strontium 87 from the body without seriously affecting the availability of Ca, Na or K in the body.

The treatment of gastric and duodenal ulcers by carrageenan is enjoying considerable popularity. Domoic acid and kainic acids have anthelmintic properties. Several preparations of kainic acids are available in the market. This represents one of the few instances in which clinically useful drugs are being manufactured from marine algae. Micro algae represent a major untapped resource of genetic potential for production of valuable bioactive agents and biochemicals. There are over 50,000 different species of micro algae of which only a few have been characterised. They are expected to furnish potent antiviral and antiAIDS agents.

References

1. Faulkner, D. J. *Nat. Prod. Rep.* **2002**, *19*, 1.
2. Erickson, K. L. In: *Marine Natural Products* (edited by P. J. Scheuer), Academic Press, N.Y. **1983**, *5*, p. 131.
3. Moore, R. E. In: *Marine Natural Products* (edited by P. J. Scheuer), Academic Press, N.Y. **1981**, *4*, p. 1.
4. Withus, N. In: *Marine Natural Products* (edited by P. J. Scheuer), Academic Press, N.Y. **1981**, *4*, p. 54.
5. Fattorusso, E.; Piateli, M. In: *Marine Natural Products* (edited by P. J. Scheuer), Academic Press, N.Y. **1983**, *3*, p. 87.
6. Chevolot, L. In: *Marine Natural Products* (edited by P. J. Scheuer), Academic Press, N.Y. **1981**, *4*, p. 54.
7. Higa, T. In: *Marine Natural Products* (edited by P. J. Scheuer), Academic Press, N.Y. **1981**, *4*, p. 93.
8. Goto, T. In: *Marine Natural Products* (edited by P. J. Scheuer), Academic Press, N.Y. **1980**, *3*, p. 180.
9. Liaaen-Jensen, S. In: *Marine Natural Products* (edited by P. J. Scheuer), Academic Press, N.Y. **1978**, *2*, p. 1.
10. Fenical, W. In: *Marine Natural Products* (edited by P. J. Scheuer), Academic Press, N.Y. **1978**, *2*, p. 173.
11. Barrow, K. D. In: *Marine Natural Products* (edited by P. J. Scheuer), Academic Press, N.Y. **1983**, *5*, 51.
12. Christophersen, C. In: *Marine Natural Products* (edited by P. J. Scheuer), Academic Press, N.Y. **1983**, *5*, p. 259.
13. Schimizu, Y.; Kamiya, H. In: *Marine Natural Products* (edited by P. J. Scheuer), Academic Press, N.Y. **1983**, *5*, p. 391.
14. Faulkner, D. J. In: *Handbook of Environmental Chemistry* (edited by O. Hutzinger), Springer Verlag, Berlin. **1980**, *1*, p. 229.
15. Fenical, W.; McConnell, D. J. In: *Marine Algae in Pharmaceutical Sciences* (edited by Y. Tanaka), Walter de Gruyter Company *Berlin*, **1979**, p. 403.
16. (a) Bhakuni, D. S.; Silva, M. *Bot. Mar.* **1974**, *17*, 40. (b) Blunt, J.W.; Copp, B.R.; Munro, M.H.G.; Northcote, P.T.; Prinsep, M.R. *Nat, Prod. Rep.* **2005**, *22*, 15.
17. Criagie, J. S.; Gruening, D. E. *Science* **1967**, *157*, 1058.
18. Irie, T. M.; Masamune, T. *Tetrahedron Lett*. **1965**, *1091*. 17.
19. Faulkner, D. J. *Nat. Prod. Rep.* **1999**, *16*, 155.
20. Faulkner, D. J. *Nat. Prod. Rep.* **1998**, *15*, 113.

21. Faulkner, D. J. *Nat. Prod. Rep.* **1997**, *14*, 259.
22. (a) Faulkner, D. J. *Nat. Prod. Rep.* **1996**, *13,* 75. (b) Irie, T.; Suzuki, M.; Masamune, T. *Tetrehedron Lett.* **1965**, 1091. (c) Irie, T.; Suzuki, M.; Masamune, T. *Tetrahedron* **1968**, *24*, 4193. (d) Cameron, A. F.; Cheung, K. K.; Ferguson, G.; Robertson, J. M. *J. Chem. Soc., Chem. Commun.* **1965**, 638. (e) Murai, A.; Murase, H.; Matsue, H.; Masamune, T. *Tetrahedron Lett.* **1977**, 2507. (f) Tsushima, K.; Murai, A, *Tetrahedron Lett.* **1992**, *33*, 4345. (g) Bratz, M.; Bullock, W. H.; Overman, L. E.; Takemoto, T. *J. Am. Chem. Soc.* **1995**, *117*, 5958. (h) Burton, J. W.; Clark, J. S.; Derrer, S.; Stork. T. C.; Bendall, J. G.; Holmes, A. B. *J. Am. Chem. Soc.* **1997**, *119*, 7483. (i) Crimmins, M. T.; Emmitte, K. A. *Org. Lett.* **1999**, *1*, 2029, (j) Mujica, M. T.; Afonso, M. M.; Galindo, A.; Palenzuela, J.A. *Synlett* **1996**, 983. (k) Krüger, J.; Hoffmann, R.W. *J. Am. Chem. Soc.* **1997**, *119*, 7499. (i) Crimmins, M. T.; Choy, A. L. *J. Am. Chem. Soc.* **1999**, *121*, 5653. (j) Baek, S.; Jo, H.; Kim, H.; Kim, H.; Kim, S.; Kim, D. *Org. Lett.* **2005**, *7*, 75.
23. (a) Irie, T.; Izawa, M.; Kurosawa. E. *Tetrahedron Lett.* **1968**, 2091. (b) Butler, A.; Carter-Franklin, J. N. *Nat. Prod. Rep.* **2004**, *21*, 180. (c) Ishihara, J.; Shimada, Y.; Kanoh, N.; Takasugi, Y.; Fukuzawa, A. Murai, A. *Tetrahedron* **1997**, *53*, 8371. (d) Fukuzawa, A.; Takasugi, Y.; Murai, A.; Nakamura, M.; Tamura, M. *Tetrahedron Lett.* **1992**, *33*, 2017. (e) Fukuzawa, A.; Aye, M.; Takasugi, Y.; Nakamura, M.; Tamura, M.; Murai, A. *Chem. Lett.* **1994**, 2307. (f) Ishihara, J.; Kanoh, N.; Murai, A. *Tetrahedron Lett.* **1995**, *36*, 737.
24. (a) Fukuzawa, A.; Takasugi, Y.; Murai, A. *Tetrahedron Lett.* **1991**, *32*, 5597. (b) Ishihara, J.; Shimada, Y.; Kanoh, N.; Takasugi, Y.; Fukuzawa, A.; Murai, A. *Tetrahedron* **1997**, *53*, 8371. (c) Irie, T.; Izawa, M.; Kurosawa, E. *Tetrahedron Lett.* **1968**, 2735. (d) Irie, T.; Izawa, M.; Kurosawa, E. *Tetrahedron* **1970**, *26*, 851. (e) Fukuzawa, A.; Kurosawa, E. *Tetrahedron Lett.* **1979**, 2797. (f) Crimmins, M. T.; Tabet, E. A. *J. Am. Chem. Soc.* **2000**, *122*, 5473.
25. (a) Takemoto, T.; Daigo, K.; Kondo, Y.; Kondo, K. *J. Pharm. Soc (Japan)* **1966**, *86*, 874. (b) Ni, Y.; Amarasinghe, K. K. D.; Ksebrti, B.; Montgomery, *J. Org. Lett.* **2003**, *5*, 3771.
26. Takemoto, T.; Daigo, K. *Chem. Pharm. Bull.* **1958**, *6*, 578.
27. Ohfune, Y.; Tomita, M. *J. Am. Chem. Soc.* **1982**, *104*, 3511.
28. Baldwin, J. E.; Moloney, M. G.; Parsons, A. F. *Tetrahedron* **1991**, *47*, 155.
29. Chandrasekaran, A.; Ponnambalam, G.; Kaur, C. *Neurotox. Res.* **2004**, *6*, 105.
30. Burkholder, P. R. *Armed Forces Chem. J.* **1963**, *27*, 1.
31. Ueno, Y.; Nawa, H.; Ueyanagi, J.; Morimoto, H.; Nakamori, R.; Matsuoka, T. *J. Pharm. Soc. (Japan)* **1955**, *75*, 835.
32. Ueno, Y.; Takana, K.; Ueyanagi, J.; Nawa, H.; Sanno,Y.; Honjo, M.; Nakamori, R.; Sugawa, T.; Uchibayashi, M.; Osugi K.; Tatsuoka, S. *Proc. Jap. Acad.* **1957**, *33*, 53.
33. Morimoto, H.; Nakamori, R. *J. Pharm. Soc. (Japan)* **1956**, *76*, 294.
34. Tanaka, K.; Miyamoto, M.; Honjo, M.; Morimoto, H.; Sugawa, T.; Uchibayashi, M.; Sanno, V.; Tatsuoka, S. *Proc. Jap. Acad. Sci.* **1957**, *33*, 47.
35. Morimoto, H. *J. Pharm. Soc. (Japan)* **1955**, *75*, 941.
36. Diago, K. *J. Pharm. Soc. (Japan)* **1956**, *76*, 109.
37. Schantz, E. J.; Mold, J. D.; Stanger, D. W.; Shavel, J.; Riel, F. J.; Sommer, H. *J. Am. Chem. Soc.* **1957**, *79*, 5230.
38. Schantz, E. J.; Lynch, J. M.; Vayuada, G.; Matsumoto, K.; Rapoport, H. *Biochem.* **1966**, *5*, 1191.
39. Schantz, E. J. In: *Animal Toxins* (edited by F. F. Russel and P. R. Saunders), Pergamon, N.Y. **1967**.

40. Daly, J. W. *J. Nat. Prod.* **2004**, *67*, 1211.
41. Schuett, W.; Rapoport, H. *J. Am. Chem. Soc.* **1962**, *84*, 2266.
42. Rapoport, H.; Mosher, H. S. *Science* **1966**, *151*, 860.
43. Nishiyama, A. *Nature (London)* **1967**, *215*, 201.
44. Kao, C. Y.; Nishiyama, A. *J. Physiol. (London)* **1966**, *211*, 997.
45. Santos, A. G.; Doty, M. S. *Lloydia* **1971**, *34*, 88.
46. Santos, A. G. *J. Chem. Soc (C)* **1970**, 842.
47. Doty, M. S.; Santos, A. G. *Nature (London)* **1966**, *211*, 990.
48. Matiti, B. C.; Thomson, R. H.; Mahendran, M. *J. Chem. Res.* **1978**, *126*.
49. Takemoto, T.; Daigo, D.; Takagi, N. *J. Pharm. Soc. (Japan)* **1964**, *84*, 1176.
50. Girard, J. P.; Marion, C.; Liutkus, M.; Boucard, M.; Rechencq, E.; Vidal, J. P.; Rossi, J. C. *Planta Med.* **1988**, *54*, 193.
51. Takemoto, T.; Daigo, K.; Takagi, N. *J. Pharm. Soc. (Japan)* **1964**, *84*, 1180.
52. Steiner, M.; Hartmann, T. *Uher Vorkommen and Verbreitung Fluchtiger Amine bei Meersalgen Plants (Berlin)* **1968**, *79*, 113.
53. Heilbron, I. M.; Parry, E. G.; Phipers, R. F. *Biochem. J.* **1935**, *29*, 1375.
54. (a) Tsuda, K.; Akagi, S.; Kishida, Y. *Science* **1957**, *126*, 927. (b) Tsuda, K.; Sakal, K.; Kishida, Y. *J. Am. Chem. Soc.* **1960**, *82*, 1442.
55. Gibbons, G.; Goad, T.; Goodwin, T. *Phytochem.* **1967**, *6*, 677.
56. Saito, A.; Idler, D. *J. Biochem.* **1966**, *44*, 1195.
57. Idler, D. A.; Saito, A.; Wiseman, P. *Steroids* **1968**, 465.
58. Meunier, H.; Zelenski, S.; Worthe, L. In: *Food Drugs from the Sea* (edited by W. Heber and H. W. Youngkenj), Marine Technology Society, Washington D.C. **1970**, p. 319.
59. Patterson, G. W. *Lipids* **1971**, *6*, 120.
60. Reiner, E.; Topliff, J.; Wood, J. D. *Can. J. Biochem. Physiol.* **1962**, *40*, 1401.
61. Upham, S. D. In: *Drugs from Sea* (edited by H. D. Freudenthal) Marine Technology Society, Washington D.C. **1968**, p. 291.
62. Mueller, G. P.; Rees, D. A. In: *Drugs from the Sea* (edited by H. D. Freudenthal), Marine Technology Society, Washington D.C. **1968**, p. 241.
63. Pernas, A. J.; Smidasord, O.; Larson, B.; Hang, A. *Acta Chem. Scand.* **1967**, *21*, 98.
64. McCandless, E. L.; Johnston, K. H. In: *Drugs from the Sea* (edited by H. D. Freudenthal), Marine Technology Society, Washington D. C., **1969**, 257.
65. Houck, L. C.; Bhayana, J.; Lee, T. *Gastroenterology* **1960**, *39*, 196.
66. Bonfils, S.; Lambing, A. *Therapie* **1960**, *15*, 612.
67. Bernfeld, P. *Biogenesis of Natural Products*, Pergamon Press Ltd., Oxford, **1963**, 307.
68. (a) McGowell, R. H. *Alginate Industries Ltd., London*, WC2, **1963**. (b) Zentilin, P., Dulbecco, P.; Savarino, E.; Parodi, A.; Iiritano, E.; Bilardi, C.; Reglioni, S.; Vigneri, S.; Savarino, V. *Aliment Pharmacol. Ther.* **2005**, *21*, 29.
69. Myers, A. E. *Can. Pharm. J.* **1965**, *98*, 28.
70. Edward, D. W. In: *Drugs from Sea* (edited by H. D. Freudenthal), Marine Technology Society, Washington, D.C. **1968**, p. 267.
71. Guven, K. C.; Aktin, E. *Bot. Mar.* **1964**, *17*, 1.
72. Elyakova, L. A.; Zvyagintseva, T. N. *Carbohydr. Res.* **1974**, *34*, 241.
73. Araki, C. *Bull. Chem. Soc. (Japan)* **1956**, *29*, 543.
74. Renn, D. W.; Mueller, G. P. In: *Drugs from the Sea* (edited by H. D. Freudenthal), Marine Technology Society, Washington D.C. **1968**, p. 277.
75. Buck, J. D.; Meyers, S. P.; Kamp, K. M. *Science* **1962**, *138*, 1339.
76. Burkholder, P. R.; Michael, R. L. S.; Sharma, G. M. *J. Antibiotics (Japan)* **1968**, *21*, 659.

77. Marderosian, A. D. in *Drugs from the Sea* (edited by H. D. Freudenthal), Marine Technology Society, Washington D.C. **1968**, p. 19.

78. Godzeski, C. W. *J. Clin. Pharmacol. Ther. Toxicol*. **1968**, 3.

79. Crawford, K. H.; Heatley, N. G.; Boyd, P. F.; Hale, C. W.; Kelly, B. K.; Miller, G. A.; Smithy, N. *J. Gen. Microbiol.* **1952**, *6*, 47.

80. Cruz, A. G. J.; Pan, T.; Giordano, R. C.; Araujo, M. L.; Hokka, C. O. *Biotechnol. Bioeng*. **2004**, *85*, 96.

81. Zhang, J.; Demain, A. L. *Biotechnol. Adv*. **1991**, *9*, 623.

82. Crawford, K.; Heatley, N. G.; Boyd, P. F.; Hale, C. W.; Kelly, B. K.; Miller, G. A.; Smith, N. *J. Gen. Microbiol*. **1952**, *6*, 47.

83. Melera, A. *Experientia* **1962**, *19*, 120.

84. Lovell, F. M. *J. Am. Chem. Soc*. **1966**, *88*, 4510.

85. Hanessian, S.; Kaltenbronn, J. S. *J. Am. Chem. Soc*. **1966**, *88*, 4509.

86. (a) Imanaka, H.; Kousaka, M.; Tamula, G.; Arima, K. *J. Antibiotics* **1965**, *18*, 207. (b) Arima, K.; Imanaka, H.; Kousaka, M.; Fukuta, A.; Tamura, G. *Agric. Biol. Chem*. **1964**, *28*, 575. (c) Aria, K.; Imanaka, H.; Kousaka, M.; Fukuda, A.; Tamura, G. *J. Antibiot*. **1965**, *18*, 201. (d) Imanaka, H.; Kousaka, M.; Tamura, G.; Arima, K. *J. Antibiot*. **1965**, *18*, 205. (e) van Pee, K.-H.; Ligon, J. M. *Nat. Prod. Rep*. **2000**, *17*, 157. (f) Howell, C. R.; Stipanovic, R. D. *Phytopathology* **1980**, *70*, 712. (g) Nishida, M.; Matsubara, T.; Watanabe, M. *J. Antibiot*. **1965**, *18*, 211. (h) Gorman, M.; Lively, D. H. in *Antibiotics*, Vol. II edited by D. Gottlieb and P. D. Shaw, Heidelberg Springer, Berlin, New York, **1967**, 433. (i) Burkhead, K. D.; Schisler, D. A.; Slinger, P. J. *Appl. Environ. Microbiol*. **1994**, *60*, 2031. (j) Lambert, B.; Leyns, F.; Van Rooyen, L.; Gosselé, F.; Papon, Y.; Swings, J. *Appl. Environ. Microbiol*. **1987**, *53*, 1866. (k) Pfender, W. F.; Kraus, J.; Loper, J. *Phytopathology* **1993**, *83*, 1223. (l) Di Santo, R.; Costi, R.; Artico, M.; Massa, S.; Lampis, G.; Deidda, D.; Pompei, R. *Bioorg. Med. Chem. Lett*. **1998**, *8*, 2931. (m) Lambowitz, A. M.; Slayman, C. W. *J. Bacteriol*. **1972**, *112*, 1020.

87. Nakano, I.; Umio, S.; Kariyone, K.; Tanaka, K.; Kishimoti, T. *J. Pharm. Soc. (Japan)* **1966**, *86*, 159.

88. Rapoport, H.; Holden, K. G. *J. Am. Chem. Soc*. **1962**, *84*, 635.

89. Llagostera, E.; Soto-Cerrato, V.; Montaner, B.; Perez-Tomas, R. *Ann. N. Y. Acad. Sci*. **2003**, *1010*, 178.

90. Perez-Tomas, R.; Montaner, B.; Llagostera, E.; Soto-Cerrato, V. *Biochem. Pharmacol*. **2003**, *66*, 1447.

91. Furstner, A. *Angew. Chem. Int. Ed. Engl*. **2003**, *42*, 3582.

92. Bennett, J. W.; Bentley, R. *Adv. Appl. Microbiol*. **2000**, *47*, 1.

93. Manderville, R. A. *Curr. Med. Chem. Anti-Canc. Agents* **2001**, *1*, 195.

94. Montaner, B.; Perez-Tomas, R. *Curr. Cancer. Drug Targets* **2003**, *3*, 57.

95. Montaner, B.; Perez-Tomas, R. *Life Sci*. **2001**, *68*, 2025.

96. D'Alessio, R.; Bargiotti, A.; Carlini, O.; Colotta, F.; Ferrari, M.; Gnocchi, P.; Isetta, A.; Mongelli, N.; Motta, P.; Rossi, A.; Rossi, M.; Tibolla, M.; Vanotti, E. *J. Med. Chem.* **2000**, *43*, 2557.

97. Schimizu, Y. *Pure Appl. Chem*. **1982**, *54*, 1973.

98. Schimizu, Y.; Hsu, C.; Fallon, W. E.; Oshima, Y.; Miura, I.; Nakanishi, K. *J. Am. Chem. Soc*. **1978**, *100*, 6791.

99. Hoyer, B. L.; Schantz, E. J.; Schnoes, H. K. *J. C. S. Chem. Comm*. **1978**, 889.

100. Wichmann, C. F.; Boyer, G. L.; Divan, C. L.; Schantz, E. J.; Schnoes, H. K. *Tetrahedron Lett*. **1981**, *22*, 1941.

101. Schimizu, Y.; Hsu, C. P. *J. C. S. Chem. Comm*. **1981**, 314.
102. Kobayashi, M.; Shimizu, Y. *J. C. S. Chem. Comm*. **1981**, 827.
103. Alam, M.; Oshima, Y.; Schimizu, Y. *Tetrahedron Lett*. **1982**, *23*, 321.
104. Lin, Y. Y.; Risk, M.; Ray, S. M.; Van Angen, D.; Clardy, J.; Golik, J.; James, J. C.; Nakanishi, K. *J. Am. Chem. Soc*. **1981**, *103*, 6773.
105. Stommel, E. W.; Watters, M. R. *Curr. Treat Options Neurol*. **2004**, *6*, 105.
106. Mattei, C.; Molgo, J.; Legrand, A. M.; Benoit, E. *J. Soc. Biol*. **1999**, *193*, 329.
107. Nicolaou, K. C.; Yang, Z.; Shi, G.; Gunzner, J. L.; Agrios, K. A.; Gartner, P. *Nature* **1998**, *392*, 264.
108. Koley, J.; Sinha, S.; Basak, A. K; Sas, M.; Dube, S. N.; Majumder, P. K., Gupta, A. K.; Dasgupta, S.; Koley, B. *Eur. J. Pharm.* **1995**, *293*, 483.
109. Alam, M.; Sanduja, R.; Hussain, M. B.; Van der Helm, D. *J. Am. Chem. Soc*. **1982**, *104*, 5232.
110. Dinovi, M.; Trainor, D. A.; Nakanishi, K.; Sanduja, R.; Alam, M. *Tetrahedron Lett*. **1983**, *24*, 855.
111. Chou, H.; Shimizu, Y.; Van Duyne, G.; Clardy, J. *Tetrahedron Lett*. **1985**, *26*, 2865.
112. Yasumoto, T.; Murata, M.; Oshima, Y.; Sano, M.; Matsumoto, G. K.; Clardy, J. *Tetrahedron* **1985**, *41*, 1019.
113. Cardellina, J. H.; Marner, F. J.; Moore, R. E. *Science* **1979**, *204*, 193.
114. Mynderse, J. S.; Moore, R.E.; Kashiwagi, M.; Norton, T. R. *Science* **1977**, *196*, 538.
115. Edwards, D. J.; Marquez, B. L.; Nogle, L. M.; McPhail, K.; Goeger, D. E.; Roberts, M. A.; Gerwick, W. H. *Chem. Biol*. **2004**, *11*, 817.
116. Williams, P. G.; Moore, R. E.; Paul, V. J. *J. Nat. Prod*. **2003**, *66*, 1356.
117. Shimizu, Y. *Curr. Opin. Microbiol*. **2003**, *6*, 236.
118. Tan, L. T.; Sitachitta, N.; Gerwick, W. H. *J. Nat. Prod.* **2003**, *66*, 764.
119. Davies-Coleman, M. T.; Dzeha, T. M.; Gray, C. A.; Hess, S.; Pannell, L. K.; Hendricks, D. T.; Arendse, C. E. *J. Nat. Prod*. **2003**, *66*, 712.
120. Nogle, L. M.; Gerwick, W. H. *J. Nat. Prod*. **2003**, *66*, 217.
121. Nogle, L. M.; Marquez, B. L.; Gerwick, W. H. *Org. Lett*. **2003**, *5*, 3.
122. MacMillan, J. B.; Molinski, T. F. *Org. Lett*. **2002**, *4*, 1535.
123. Osborne, N. J.; Webb, P. M.; Shaw, G. R. *Environ. Int*. **2001**, *27*, 81.
124. Luesch, H.; Pangilinan, R.; Yoshida, W. Y.; Moore, R. E.; Paul, V. J. *J. Nat. Prod*. **2001**, *64*, 304.
125. Marquez, B.; Verdier-Pinard, P.; Hamel, E.; Gerwick, W. H. *Phytochemistry* **1998**, *49*, 2387.
126. Todd, J. S.; Gerwick, W. H. *J. Nat. Prod*. **1995**, *58*, 586.
127. Simmons, C. J.; Marner, F. J.; Cardellina, J. H.; Moore, R. E.; Seff, K. *Tetrahedron Lett*. **1979**, 2003.
128. Cardellina, J. H.; Moore, R. E. *Tetrahedron Lett*. **1979**, 2007.
129. Carter, D. C.; Moore, R. E.; Mynderse, J. S.; Niemezure, W. P.; Todd, J. S. *J. Org. Chem*. **1984**, *49*, 236.
130. Stewart, J. B.; Bornemann, V.; Chem, J. L.; Moore, R. E.; Caplan, F. R.; Kaluso, H.; Larsen, L. K.; Patterson, G. M. L. *J. Antibiot*. **1988**, *41*, 1048.
131. Stjerulof, P.; Trogen, L.; Aderson, A. *Acta Chem. Scand., Ser. B*. **1989**, *43*, 917.
132. Paul, V. J.; Fenical, W. *Science* **1983**, *221*, 747.
133. Linares, A. F.; Loikkanen, J.; Jorge, M. F.; Soria, R. B.; Novoa, A. V. *Vet. Hum. Toxicol*. **2004**, *46*, 1.
134. Fallarero, A.; Loikkanen, J. J.; Mannisto, P. T.; Castaneda, O.; Vidal, A. *Phytomedicine* **2003**, *10*, 39.
135. Paul, V. J.; Fenical, W. *Tetrahedron* **1984**, *40*, 3053.

136. Tillekeratne, M. V.; Schimitz, F. J. *Phytochem*. **1984**, *23*, 1331.
137. Sun, H. H.; Ferrara, N. M.; McConnell, O. J.; Fenical, W. *Tetrahedron Lett*. **1980**, *21*, 3123.
138. Ochi, M.; Kotsuki, H.; Muraoka, K.; Tokoroyama, T. *Bull. Chem. Soc. (Japan)* **1979**, *52*, 831.
139. Ochi, M.; Kotsuki, H.; Inoue, S.; Taniguchi, M.; Tokoroyama, T. *Chem. Lett*. **1979**, 831.
140. Moore, R. E. *Acc. Chem. Res*. **1977**, *10*, 40.
141. Muller, D. G.; Gassmann, G.; Boland, W.; Marner, F. J.; Jaenicke, L. *Science* **1981**, *212*, 1040.
142. Muller, D. G.; Gassmann, G.; Marner, F. J.; Boland, W.; Jaenicke, L. *Science* **1982**, *218*, 1119.
143. Edmonds, J. S.; Francesconi, K. A. *Nature* **1981**, *289*, 602.
144. Edmonds, J. S.; Francesconi, K. A. *J. Chem. Soc. Perkin Trans-I* **1983**, 2375.
145. Tanaka, J.; Higa, T. *Chem. Lett*. **1984**, 231.
146. De Rosa, S.; De Stefano, S.; Macura, S.; Trivellone, E.; Zavodnik, N. *Tetrahedron* **1984**, *40*, 4991.
147. Tringali, C.; Piattelli, M.; Nicolosi, G. *Tetrahedron* **1984**, *40*, 799.
148. Fukuyama, T.; Kodama, M.; Miura, I.; Kinzyo, Z.; Kido, M.; Mori, H.; Nakayama, Y.; Takahashi, M. *Chem. Pharm. Bull*. **1989**, *37*, 171.
149. Jormalainen, V.; Honkanen, T. *J. Evol. Biol*. **2004**, *17*, 807.
150. Ahn, M. J.; Yoon, K. D.; Min, S. Y.; Lee, J. S.; Kim, J. H.; Kim, T. G.; Kim, S. H.; Kim, N. G.; Huh, H.; Kim, *J. Biol. Pharm. Bull*. **2004**, *27*, 544.
151. Nagayama, K.; Iwamura, Y.; Shibata, T.; Hirayama, I.; Nakamura, T. *J. Antimicrob. Chemother*. **2002**, *50*, 889.
152. Glombitza, K. W.; Schmidt, A. *J. Nat. Prod*. **1999**, *62*, 1238.
153. Watanabe, K.; Umeda, K.; Miyakado, M. *Agr. Biol. Chem*. **1989**, *53*, 2513.
154. Ohira, S.; Shirane, F.; Nozaki, H.; Yahiro, S.; Nakayama, M. *Bull. Chem. Soc. Japan* **1989**, *62*, 2427.
155. Nozaki, H.; Minohara, K. *Agr. Biol. Chem*. **1988**, *52*, 3229.
156. Kazlauskas, R.; Murphy, P.T.; Wells, R. J.; Baid-Lambert, J. A.; Jamieson, D. D. *Aust. J. Chem*. **1983**, *36*, 165.
157. Prati, M.; Molteni, M.; Pomati, F.; Rossetti, C.; Berhadini, G. *Toxicon* **2002**, *40*, 267.
158. Burja, A. M.; Abou-Mansour, E.; Banaigs, B.; Payri, C.; Burgess, J. G. *J. Micro Methods* **2002**, *48*, 207.
159. Chang, Z.; Sitachitta, N.; Rossi, J. V.; Roberts, M. A.; Flatt, P. M.; Jia, J.; Sherman, D. H.; Gerwick, W. H. *J. Nat. Prod*. **2004**, *67*, 1356.
160. White, J. D.; Xu, Q.; Lee, C. S.; Valeriote, F. A. *Org. Biomol. Chem*. **2004**, *2*, 2092.
161. Edwards, D. J.; Marquez, B. L.; Nogle, L. M.; McPhail, K.; Goeger, D. E.; Roberts, M. A.; Gerwick, W. H. *Chem. Biol*. **2004**, *11*, 817.
162. Tan, L. T.; Sitachitta, N.; Gerwick, W. H. *J. Nat. Prod*. **2003**, *66*, 764.
163. Williamson, R. T.; Singh, I. P.; Gerwick, W. H. *Tetrahedron* **2004**, *60*, 7025.
164. Izumi, A. K.; Moore, R. E. *Clin. Dermatol*. **1987**, *5*, 92.
165. Singh, I. P.; Milligan, K. E.; Gerwick, W. H. *J. Nat. Prod*. **1999,** *62,* 1333.
166. Yamada, T.; Iwamoto, C.; Yamagoki, N.; Yamanouchi, T.; Minoura, K.; Yamori, T.; Uehara, Y.; Andoh, T.; Umemura, K.; Numata, A. *Tetrahedron* **2002**, *58*, 479.
167. Jiang, Z. D.; Jensen, P. R.; Fenical, W. *Bioorg. Med. Chem. Lett*. **1999**, *9*, 2003.
168. Berge, J. P.; Bourgougnon, N.; Alban, S.; Pojer, F.; Billaudel, S.; Chermann, J. C.; Robert, J.M.; Franz, G. *Planta Med*. **1999**, *65*, 604.

169. Flodin, C.; Whitefield, F. D. *Phytochem.* **2000**, **53**77.
170. Huheihel, M.; Ishanu, V.; Tal, J.; Shoshana, A. *J. Biochem. Biophy. Methods* **2002**, *50*, 189.
171. Osterhage, C.; Konig, G. M.; Holler, U.; Wright, A. D. *J. Nat. Prod*. **2002**, *65*, 306.
172. Koyanagi, S.; Tanigawa, N.; Nakagawa, H.; Soeda, S.; Shimeno, H. *Biochem. Pharma*. **2003**, *65*, 173.
173. Zhou, G.; Sun, Y.; Xin, H.; Zhang, Y.; Li, Z.; Xu, Z. *Pharm. Res*. **2004**, *50*, 47.
174. Teramoto, M.; Rahlert, N.; Misawa, N.; Sandmann, G. *FEBS Lett*. **2004**, *570*, 184.
175. O'Brien, A.; Sharp, R.; Russell, N. J.; Roller, S. *FEMS Microb. Ecol.* **2004**, *48*, 157.